IGFBP-1 ELISA

$302.00
Catalog
11-IGFHU-E01
The IGFBP-1 ELISA is for the direct quantitative determination of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) by an enzyme immunoassay in human serum. For Research Use Only. Not for Use in Diagnostic Procedures.

Dynamic range
1-250 ng/mL

Sensitivity
0.5 ng/mL

Sample size
25 µL

Species
Human
Regulatory Status
Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available Worldwide
Range
1 - 250 µg/L
Sensitivity
0.5 µg/L
Sizes
96 Wells
Sample Types
Serum
Inc Time Hour
1
Inc Time Minute
10
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
25
Detection
Colorimetric

Insulin-like growth factor binding protein-1 (IGFBP-1) is one of six proteins that specifically bind insulin-like growth factors I and II (IGF-I and IGF-II) in body fluids and tissues. IFGBP-1 contains 234 amino acids, with a predicted molecular mass of 25 kDa. The major sites of IGFBP-1 synthesis are the fetal /adult liver and decidualized endometrium. Serum levels of IGFBP-1, which reflect its synthesis by the liver, exhibit considerable diurnal variation. Circulating IGFBP-1 levels are highest early in the morning and lowest in the evening. The levels are high in the fetus and newborn, but decline steadily until puberty. The mean level of IGFBP-1 in healthy adults is 4.4 µg/l (range 0.6-14.4 µg/l). After about 65 years of age, serum IGFBP-1 levels begin to increase. There is also an inverse correlation between body mass index (BMI) and fasting serum IGFBP-1 concentrations. 

The most important regulator of circulating IGFBP-1 is insulin. Fasting insulin and IGFBP-1 concentrations are inversely correlated. During a 3-h glucose tolerance test, there is a decrease of about 50% in serum IFGBP-1 levels. Eating a meal also has a decreasing effect. In insulin-dependent diabetes (IDDM), serum IGFBP-1 levels are elevated. In non-insulin dependent diabetes, in which insulin levels are high, serum IGFBP-1 is decreased. Low levels of IGFBP-1 have also been observed in the following cases: acromegaly, Cushing’s syndrome and polycystic ovarian syndrome (PCO).

IGFBP-1 ELISA

11-IGFHU-E01

Billing Address

Shipping Address

Resources to advance your discoveries 

Recent posts

8 Questions to Ask Before Choosing an Allergy Testing Platform
8 Questions to Ask Before Choosing an Allergy Testing Platform
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
View Now
Understanding IgE Allergy Test Results
Understanding IgE Allergy Test Results
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
View Now
Improving Food Elimination Diets with IgG Testing
Improving Food Elimination Diets with IgG Testing
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
View Now

Recent posts

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Salem, NH, April 25, 2024 – Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the...
View Now
Targeted Solutions for Gastroenterology
Targeted Solutions for Gastroenterology
ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.
View Now
 Optimizing IBD Management with Fecal Calprotectin: From Diagnosis to Monitoring
Webinar On-Demand: Optimizing IBD Management with Fecal Calprotectin - From Diagnosis to Monitoring
In the webinar, Dr. Benjamin Click from the University of Colorado, Department of Gastroenterology, underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals..
View Now

Biomarkers of Energy Homeostasis Brochure

Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.

Complement System Solutions for Drug Development and Clinical Research Datasheet

The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.

Melatonin Products for Sleep Disorder-Related Research Datasheet

The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.